Education
About Us
Working with TipRanks
Follow Us
Cue Biopharma Inc (CUE)
NASDAQ:CUE
Cue-102
Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer, Gastric Cancer
Phase I
Completed
A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
Apr 19, 2022
―
Cue-101, Keytruda®, Pembrolizumab
Head And Neck Cancer, Hpv Positive Oropharyngeal Squamous Cell Carcinoma, Hpv-Related Carcinoma
Phase I
Active Not Recruiting
A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma
Jun 04, 2019
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Cue Biopharma Inc (CUE) have in its pipeline
CUE is currently developing the following drugs: Cue-102, Cue-101, Keytruda®, Pembrolizumab. These drug candidates are in various stages of clinical development as the company works toward FDA approval.